Prytime Medical Devices, Inc. Market Research Report

Background

Prytime Medical Devices, Inc., established in 2014 and headquartered in Boerne, Texas, specializes in the design, development, and commercialization of minimally invasive solutions for hemorrhage control. The company's mission is to improve trauma outcomes through innovative medical devices, with a particular focus on Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) technology. Their flagship product, the ER-REBOA™ Catheter, is a 7 Fr compatible balloon catheter designed for rapid, temporary occlusion of large vessels in emergency and critical care settings.

Key Strategic Focus

Prytime Medical's strategic focus centers on advancing REBOA technology to enhance patient outcomes in trauma and critical care scenarios. The company emphasizes:

Core Objectives: Developing and commercializing innovative medical devices that provide rapid hemorrhage control and support resuscitation efforts.

Areas of Specialization: Minimally invasive solutions for hemorrhage control, particularly in trauma and emergency medicine.

Key Technologies: REBOA catheters, including the ER-REBOA™ and pREBOA-PRO™ catheters.

Primary Markets: Military and civilian trauma centers, emergency departments, and critical care units.

Financials and Funding

Prytime Medical has secured funding to support its growth and product development initiatives:

Total Funds Raised: Approximately $11.3 million over three funding rounds.

Recent Funding Round: In June 2021, the company closed an oversubscribed $6 million inside financing round to fuel commercialization growth.

Notable Investors: Specific investors are not publicly disclosed.

Utilization of Capital: The funds are intended to support the commercialization of new products, enhance customer support, and improve clinical outcomes.

Pipeline Development

Prytime Medical's product pipeline includes:

pREBOA-PRO™ Catheter: Designed for true partial REBOA, allowing for prolonged aortic occlusion times up to 2 hours, thereby expanding treatment options and potentially reducing complications associated with complete occlusion.

ER-REBOA™ PLUS Catheter: An enhanced version of the original ER-REBOA™ Catheter, featuring improvements such as "landing zone" markers, length markers, and guidewire compatibility.

Technological Platform and Innovation

Prytime Medical's technological innovations include:

Proprietary Technologies:

pREBOA-PRO™ Catheter: The first FDA-cleared REBOA catheter designed specifically for true partial REBOA, featuring a unique Prune Balloon™ design that allows for manual titration of blood flow.

ER-REBOA™ PLUS Catheter: Incorporates features such as "landing zone" markers and guidewire compatibility to enhance ease of use and effectiveness.

Significant Scientific Methods:

True Partial REBOA™: Enables controlled partial occlusion of the aorta, allowing for prolonged occlusion times and reducing the risk of ischemic complications.

Leadership Team

David Spencer: Co-Founder, President, Chief Executive Officer, and Director.

Julie Burgett: Senior Vice President, Research and Product Development.

Brian Young: Senior Vice President, Quality & Regulatory.

David Baer: Chief Scientific Officer.

Leadership Changes

Andrew Holman: Appointed as Chief Commercialization Officer in October 2020.

Competitor Profile

Market Insights and Dynamics

The market for minimally invasive hemorrhage control solutions is expanding, driven by the need for effective trauma care in both military and civilian settings. The adoption of REBOA technology is increasing as healthcare providers seek advanced methods to manage non-compressible torso hemorrhage.

Competitor Analysis

Key competitors include:

410 Medical: Develops medical devices for emergency and critical care, focusing on rapid fluid delivery systems.

Alydia Health: Specializes in solutions for postpartum hemorrhage, offering devices designed to control bleeding after childbirth.

Infuseon Therapeutics: Develops therapeutic delivery devices, such as the Cleveland Multiport Catheter, for targeted drug delivery.

Advanced Catheter Therapies: Focuses on developing catheter technologies for various medical applications.

Strategic Collaborations and Partnerships

Red One Medical: In June 2021, Prytime Medical partnered with Red One Medical to supply life-saving medical devices to the U.S. military, enhancing the availability of REBOA technology in combat medicine.

Operational Insights

Prytime Medical differentiates itself through:

Innovative Product Design: Development of the pREBOA-PRO™ Catheter, enabling true partial REBOA and extended occlusion times.

Military-Civilian Integration: Leveraging military medical innovations for civilian trauma care applications.

Comprehensive Training and Support: Establishing Centers of Excellence to provide extensive training and support for healthcare providers implementing REBOA technology.

Strategic Opportunities and Future Directions

Prytime Medical aims to:

Expand Global Reach: Continue international expansion, as evidenced by the first civilian use of the pREBOA-PRO™ Catheter in Europe following CE Mark approval.